Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE), and others in the coronavirus vaccine race are approaching the finish line. This week, Pfizer and its partner BioNTech (NASDAQ:BNTX) reported positive interim efficacy data from their phase 3 trial. Moderna and the Pfizer team have each said they expect phase 3 safety data this month, after which they will apply for an emergency use authorization (EUA) from the U.S Food and Drug Administration.
Well before now, however, clues were emerging about which companies may become the biggest vaccine suppliers. Months ago, pharmaceutical companies and biotech rivals began announcing agreements to supply organizations and countries with doses, following vaccine approvals. Let's take a look at where things stand today for some of the most significant participants in this race.
